Antimicrobial Agents Practice Questions

Q: What is true about clavulanic acid?

It is a beta-lactamase inhibitor.. **Explanation:** **Clavulanic acid** is a classic example of a **beta-lactamase inhibitor**. It contains a beta-lactam ring but possesses negligible intrinsic antibacterial activity. Its primary mechanism involves acting as a "suicide inhibitor"; it binds irreversibly to the active site of beta-lactamase enzymes produced by bacteria, thereby preventing these enzymes from destroying co-administered beta-lactam antibiotics (like Amoxicillin). **Analysis of Options:** * **Option A (Correct):** It inhibits beta-lactamases (specifically Richmond-Sykes types II through V, including staphylococcal penicillinases and plasmid-mediated beta-lactamases). * **Option B (Incorrect):** Extended-spectrum penicillins refer to drugs like Aminopenicillins (Amoxicillin) or Antipseudomonal penicillins (Piperacillin). Clavulanic acid is a non-antibiotic structural analogue. * **Option C (Incorrect):** On its own, clavulanic acid has no significant clinical activity against Gram-negative or Gram-positive bacteria. It only restores the activity of other antibiotics. * **Option D (Incorrect):** While it inhibits enzymes often encoded by plasmids, it does not inhibit the plasmid (DNA) itself. **High-Yield NEET-PG Pearls:** 1. **Common Combinations:** Amoxicillin + Clavulanic acid (Co-amoxiclav) and Ticarcillin + Clavulanic acid. 2. **Other Inhibitors:** Sulbactam, Tazobactam (often paired with Piperacillin), and newer non-beta-lactam inhibitors like **Avibactam** and **Vaborbactam**. 3. **Spectrum:** It is ineffective against Class C (AmpC) beta-lactamases and Metallo-beta-lactamases (NDM-1). 4. **Side Effect:** Co-amoxiclav is a frequent cause of drug-induced cholestatic jaundice.

Q: Which of the following is NOT an anti-Helicobacter pylori drug?

Sucralfate. **Explanation:** The management of *Helicobacter pylori* infection requires a combination of antibiotics and acid-suppressing agents to eradicate the bacteria and promote ulcer healing. **Why Sucralfate is the Correct Answer:** Sucralfate is a **cytoprotective agent**, not an antimicrobial. It is a complex of aluminum hydroxide and sulfated sucrose that polymerizes in an acidic environment (pH < 4) to form a sticky, viscous gel. This gel binds to the base of the ulcer crater, creating a physical barrier against acid, pepsin, and bile. While it aids in ulcer healing, it has **no direct inhibitory or bactericidal effect** on *H. pylori*. **Analysis of Incorrect Options:** * **Amoxicillin:** A penicillin that inhibits bacterial cell wall synthesis. It is a cornerstone of *H. pylori* therapy due to low resistance rates. * **Clarithromycin:** A macrolide that inhibits protein synthesis (50S subunit). It is the most potent antibiotic against *H. pylori* but is susceptible to increasing resistance. * **Metronidazole:** A nitroimidazole that causes DNA strand breakage. It is used as an alternative to amoxicillin in penicillin-allergic patients or as part of quadruple therapy. **High-Yield Clinical Pearls for NEET-PG:** * **First-line Treatment (Standard Triple Therapy):** Proton Pump Inhibitor (PPI) + Clarithromycin + Amoxicillin (or Metronidazole) for 10–14 days. * **Bismuth Quadruple Therapy:** PPI + Bismuth subsalicylate + Metronidazole + Tetracycline (Used in areas with high clarithromycin resistance). * **Sucralfate Fact:** It requires an acidic medium to work; therefore, it should **not** be administered simultaneously with antacids or PPIs (give it 30 minutes before).

Q: Which of the following is NOT true about aminoglycosides?

They are bacteriostatic.. **Explanation:** **1. Why Option A is the correct answer:** Aminoglycosides (e.g., Gentamicin, Amikacin, Streptomycin) are **bactericidal**, not bacteriostatic. They bind irreversibly to the **30S ribosomal subunit**, causing mRNA misreading and the synthesis of abnormal proteins. These "faulty" proteins insert into the bacterial cell membrane, leading to increased permeability and rapid cell death. This irreversible binding and subsequent membrane damage distinguish them from most other protein synthesis inhibitors (like Tetracyclines or Macrolides), which are typically bacteriostatic. **2. Analysis of incorrect options:** * **Option B (Distributed extracellularly):** Aminoglycosides are highly polar, polycationic compounds. Because of this charge, they do not cross lipid membranes easily and are largely confined to the **extracellular fluid (ECF)**. They have a low volume of distribution ($V_d$). * **Option C (Excreted unchanged in urine):** They are not metabolized by the liver. They are excreted entirely by **glomerular filtration** in their active, unchanged form. This makes dosage adjustment critical in patients with renal impairment. * **Option D (Teratogenic):** Aminoglycosides are known to cross the placenta and can cause **8th cranial nerve damage (ototoxicity)** in the fetus. Streptomycin, in particular, is associated with congenital deafness. **Clinical Pearls for NEET-PG:** * **Spectrum:** Primarily active against **Aerobic Gram-negative bacilli**. They require oxygen for transport into the cell; hence, they are ineffective against anaerobes. * **Toxicity:** Characterized by **Ototoxicity** (vestibular/cochlear) and **Nephrotoxicity** (Acute Tubular Necrosis). * **Pharmacokinetics:** They exhibit **Concentration-dependent killing** and a significant **Post-Antibiotic Effect (PAE)**, allowing for once-daily dosing.

Q: All of the following drugs are useful in typhoid fever except?

Amikacin. **Explanation:** The correct answer is **Amikacin**. **1. Why Amikacin is the correct answer:** Typhoid fever (Enteric fever) is caused by *Salmonella typhi*, an **intracellular** pathogen. Amikacin is an Aminoglycoside; these drugs are highly polar, polycationic molecules that do not easily penetrate cell membranes. Consequently, they have poor intracellular penetration and are ineffective against intracellular organisms like *Salmonella*. Furthermore, Aminoglycosides are primarily active against aerobic extracellular gram-negative bacilli and are not clinically indicated for typhoid. **2. Analysis of incorrect options:** * **Ceftriaxone (Option B):** Currently the **drug of choice** for empirical treatment of typhoid fever, especially in cases of multidrug resistance (MDR) or quinolone resistance. It is highly effective and administered parenterally. * **Cefixime (Option A):** An oral third-generation cephalosporin used as an effective alternative for step-down therapy or in uncomplicated cases where parenteral administration is not feasible. * **Quinolones (Option D):** Drugs like Ciprofloxacin were historically the first-line treatment. Although resistance (NALC - Nalidixic acid-resistant *S. typhi*) is rising, they remain a therapeutic option based on sensitivity patterns. **3. High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (Empirical):** Ceftriaxone. * **Drug of Choice (Sensitive strains):** Fluoroquinolones (e.g., Ciprofloxacin). * **Carrier State:** Ampicillin or Cholecystectomy (if gallstones are present). * **Azithromycin:** Now frequently used for uncomplicated typhoid due to increasing resistance to other oral agents. * **Mechanism of Resistance:** Resistance in *Salmonella* is often mediated by R-plasmids.

Q: If amphotericin B is administered, the patient should be premedicated with:

Any of the above. **Explanation:** Amphotericin B is notorious for causing **infusion-related reactions** (often called "shake and bake" reactions), characterized by fever, chills, rigors, hypotension, and headache. These reactions occur due to the release of pro-inflammatory cytokines (TNF-α and IL-1) from host macrophages and monocytes. To mitigate these side effects, premedication is standard clinical practice: * **Diphenhydramine (Antihistamine):** Helps reduce minor allergic symptoms and histamine-mediated components of the reaction. * **Ibuprofen/Acetaminophen (NSAIDs/Antipyretics):** Effectively target the prostaglandin-mediated fever and chills. * **Prednisone/Hydrocortisone (Corticosteroids):** Used in more severe cases to suppress the overall inflammatory cytokine surge. Since all three classes of drugs are utilized to manage different aspects of the infusion-related toxicity, **"Any of the above"** is the correct choice. **Why other options are not "wrong" but incomplete:** While each individual drug (A, B, or C) is used, selecting only one would ignore the established clinical utility of the others. In NEET-PG, when multiple standard-of-care treatments are listed for a single condition, the "all of the above" option is typically the intended answer. **High-Yield Clinical Pearls for NEET-PG:** * **Dose-Limiting Toxicity:** Nephrotoxicity (permanent damage) is the most serious long-term side effect. * **Liposomal Amphotericin B:** Developed to reduce nephrotoxicity and infusion reactions by targeting the drug more specifically to fungal cells. * **Electrolyte Imbalance:** Always monitor for **Hypokalemia** and **Hypomagnesemia** due to renal tubular damage. * **Test Dose:** A small 1mg test dose is often given to gauge the severity of the reaction before the full infusion.

Q: What is the drug of choice in systemic candidiasis?

Amphotericin. **Explanation:** **Amphotericin B** remains the "Gold Standard" and drug of choice for most life-threatening systemic fungal infections, including **systemic candidiasis**, cryptococcal meningitis, and invasive aspergillosis. Its mechanism of action involves binding to **ergosterol** in the fungal cell membrane, creating pores that lead to the leakage of intracellular contents and cell death (fungicidal). **Analysis of Options:** * **Amphotericin B (Correct):** It has the broadest spectrum of activity and is preferred for severe, disseminated, or deep-seated candidal infections (e.g., candidemia, endocarditis). * **Griseofulvin:** This is an oral antifungal used exclusively for **dermatophytosis** (skin, hair, and nail infections). It is ineffective against Candida and systemic mycoses. * **Nystatin:** While structurally similar to Amphotericin B, it is **highly toxic** if given parenterally. Therefore, its use is restricted to **topical** applications for mucosal candidiasis (e.g., oral thrush, vaginal candidiasis). * **Ketoconazole:** An older azole that is now rarely used systemically due to its narrow spectrum, significant drug interactions, and risk of **hepatotoxicity** and adrenal suppression. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects of Amphotericin B:** The most common is **nephrotoxicity** (azotemia). It also causes infusion-related reactions ("shake and bake" – fever/chills) and hypokalemia. * **Liposomal Amphotericin B:** This formulation is preferred as it significantly reduces nephrotoxicity by targeting the drug specifically to fungal cells. * **Alternative:** In hemodynamically stable patients, **Echinocandins** (e.g., Caspofungin) are now often used as first-line therapy for candidemia, but Amphotericin B remains the definitive answer for systemic coverage in exams.

Q: MRSA is resistant to which class of antibiotics?

Beta-lactams. **Explanation:** **1. Why Beta-lactams are the correct answer:** Methicillin-resistant *Staphylococcus aureus* (MRSA) is defined by its resistance to nearly all beta-lactam antibiotics (penicillins, cephalosporins, carbapenems). The underlying mechanism is the **alteration of the target site**. MRSA possesses the **mecA gene**, which encodes a modified Penicillin-Binding Protein called **PBP-2a**. Unlike normal PBPs, PBP-2a has a very low affinity for beta-lactam rings, rendering these drugs unable to inhibit cell wall synthesis. **2. Analysis of Incorrect Options:** * **A. Vancomycin:** This is a glycopeptide and remains the traditional **drug of choice** for serious MRSA infections. It acts by binding to the D-Ala-D-Ala terminus of nascent peptidoglycan, a different site than PBPs. * **C. Linezolid:** An oxazolidinone that inhibits protein synthesis (50S subunit). It is highly effective against MRSA and is often used for MRSA pneumonia or skin infections. * **D. Meropenems:** These belong to the Carbapenem class. Since carbapenems are beta-lactams, MRSA is inherently resistant to them due to the PBP-2a modification. (Note: While Meropenem is a beta-lactam, the question asks for the *class* it belongs to, making "Beta-lactams" the more fundamental and inclusive answer). **3. High-Yield Clinical Pearls for NEET-PG:** * **The Exception:** **Ceftaroline** (a 5th generation cephalosporin) is the **only** beta-lactam that has activity against MRSA because it can bind to PBP-2a. * **VRSA/VISA:** Resistance to Vancomycin occurs via the **vanA gene**, which changes D-Ala-D-Ala to **D-Ala-D-Lac**. * **DOC for MRSA:** Vancomycin (IV); for MRSA skin infections (outpatient), Clindamycin or Co-trimoxazole can be used.

Q: Renal damage due to amphotericin B include all the following except:

Glomerulonephritis. **Explanation:** Amphotericin B is notorious for its dose-dependent nephrotoxicity, which occurs via two primary mechanisms: **direct toxicity** to the renal tubular epithelium and **pre-renal vasoconstriction** of the afferent arterioles. **Why Glomerulonephritis is the Correct Answer:** Glomerulonephritis is an inflammatory process typically mediated by immune complexes or antibodies (e.g., Post-streptococcal GN). Amphotericin B causes **tubular and vascular damage**, not an immunological glomerular inflammation. While it reduces the Glomerular Filtration Rate (GFR) due to vasoconstriction, it does not cause "Glomerulonephritis" pathologically. **Analysis of Incorrect Options:** * **Azotemia:** This is the most common side effect. Amphotericin B causes constriction of the afferent arterioles, leading to decreased renal blood flow and a rise in serum creatinine and BUN (azotemia). * **Renal Tubular Acidosis (RTA):** Amphotericin B increases the permeability of the distal tubular membrane. This leads to a "leak" of hydrogen ions, resulting in **Type 1 (Distal) RTA**. * **Hypokalemia:** The increased membrane permeability also causes significant wasting of potassium and magnesium. This electrolyte imbalance is a classic hallmark of Amphotericin-induced renal damage. **NEET-PG High-Yield Pearls:** * **Liposomal Amphotericin B:** Developed to reduce nephrotoxicity by targeting the drug specifically to fungal ergosterol rather than human cholesterol in renal cells. * **Saline Loading:** Administering 1 liter of normal saline before infusion ("salt loading") is the standard clinical practice to reduce the risk of nephrotoxicity. * **Anemia:** Amphotericin B can also cause normocytic normochromic anemia due to decreased erythropoietin production by the damaged kidneys.

Q: Which one of the following therapies would be safe in a patient with pulmonary tuberculosis having markedly abnormal liver function?

Streptomycin + ethambutol. ### Explanation The management of pulmonary tuberculosis in patients with pre-existing liver disease or markedly abnormal liver function tests (LFTs) requires the avoidance of **hepatotoxic** drugs. **1. Why Option D is Correct:** Both **Streptomycin** and **Ethambutol** are considered non-hepatotoxic. * **Streptomycin** is an aminoglycoside excreted primarily by the kidneys; its main toxicities are ototoxicity and nephrotoxicity. * **Ethambutol** is an antimetabolite excreted in the urine; its primary side effect is optic neuritis. Since neither drug undergoes significant hepatic metabolism or causes drug-induced liver injury (DILI), they are the safest combination for a patient with liver failure. **2. Why Other Options are Incorrect:** * **Isoniazid (INH):** A major component of Options A, B, and C. It is highly hepatotoxic, especially in "slow acetylators," due to the formation of toxic metabolites like acetylhydrazine. * **Rifampicin:** Included in Option C. It is a potent inducer of microsomal enzymes and can cause cholestatic jaundice. When combined with INH, the risk of hepatotoxicity increases synergistically. * **Pyrazinamide (not listed but relevant):** This is the **most hepatotoxic** of all first-line anti-tubercular drugs (ATDs) and must be avoided in liver disease. **3. NEET-PG High-Yield Pearls:** * **Hepatotoxicity Ranking:** Pyrazinamide > Isoniazid > Rifampicin. * **Safe in Liver Disease:** "SHE" (Streptomycin, Ethambutol). * **Safe in Renal Failure:** Rifampicin and Isoniazid (as they are primarily metabolized/excreted via the liver/bile). Ethambutol and Streptomycin require dose adjustment or avoidance in renal failure. * **WHO Guidelines for Liver Disease:** If the patient has stable chronic liver disease, a regimen like **2SHRE/6HE** or **2HRE/6HE** may be used. In advanced/unstable cirrhosis, the safest regimen is **Streptomycin + Ethambutol + a Fluoroquinolone** for 18–24 months.

Question 1

What is true about clavulanic acid?

Accepted Answer

It is a beta-lactamase inhibitor.

Answer

It is an extended-spectrum penicillin.

Answer

It is effective against Gram-negative bacteria.

Answer

It is a plasmid inhibitor.

Question 2

Which of the following is NOT an anti-Helicobacter pylori drug?

Accepted Answer

Sucralfate

Answer

Amoxicillin

Answer

Clarithromycin

Answer

Metronidazole

Question 3

Which of the following is NOT true about aminoglycosides?

Accepted Answer

They are bacteriostatic.

Answer

They are distributed only extracellularly.

Answer

They are excreted unchanged in urine.

Answer

They are teratogenic.

Question 4

All of the following drugs are useful in typhoid fever except?

Accepted Answer

Amikacin

Answer

Cefixime

Answer

Ceftriaxone

Answer

Quinolones

Question 5

If amphotericin B is administered, the patient should be premedicated with:

Accepted Answer

Any of the above

Answer

Diphenhydramine

Answer

Ibuprofen

Answer

Prednisone

Question 6

What is the drug of choice in systemic candidiasis?

Accepted Answer

Amphotericin

Answer

Griseofulvin

Answer

Nystatin

Answer

Ketoconazole

Question 7

MRSA is resistant to which class of antibiotics?

Accepted Answer

Beta-lactams

Answer

Vancomycin

Answer

Linezolid

Answer

Meropenems

Question 8

Renal damage due to amphotericin B include all the following except:

Accepted Answer

Glomerulonephritis

Answer

Azotemia

Answer

Renal tubular acidosis

Answer

Hypokalemia

Question 9

Which one of the following therapies would be safe in a patient with pulmonary tuberculosis having markedly abnormal liver function?

Accepted Answer

Streptomycin + ethambutol

Answer

Streptomycin + isoniazid

Answer

Ethambutol + isoniazid

Answer

Rifampicin + isoniazid

Question 10

The mechanism of action of tetracyclines involves:

Accepted Answer

Blockade of binding of aminoacyl-tRNA to bacterial ribosomes by binding to 30S ribosome

Answer

Binding of a component of the 50S ribosomal subunits

Answer

Inhibition of translocase activity

Answer

Selective inhibition of ribosomal peptidyl transferase

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?